ArticleOncology letters2018
Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Discovery and Optimization of AMT-676, a CDH17-Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A Validated, explainable machine learning-based preoperative risk model for microvascular invasion in hepatocellular carcinoma.Langenbeck's archives of surgery · 2026Article
- Cadherin 17 and digestive cancers: from diagnostic to therapeutic opportunities.Journal of experimental & clinical cancer research : CR · 2026Review
- Label-free quantitative proteomics of gastric high-grade intraepithelial neoplasia.Experimental and therapeutic medicine · 2025Article
- [Correlation analysis between expression of cytokeratin 19 and clinical pathological characteristics and prognosis of dual-phenotype hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy.World journal of surgical oncology · 2022Article
- Article
- Synthesis and characterization of magnetic nanoparticles coated with polystyrene sulfonic acid for biomedical applications.Science and technology of advanced materials · 2020Article
- Transcriptomic analysis to affirm the regulatory role of long non-coding RNA in horn cancer of Indian zebu cattle breed Kankrej (Bos indicus).Functional & integrative genomics · 2020Article
- CK19-positive Hepatocellular Carcinoma is a Characteristic Subtype.Journal of Cancer · 2020Review
- Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal?Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A previous study demonstrated that cytokeratin 19 (CK19) expression in hepatocellular carcinoma (HCC) is an indicator of HCC invasiveness, including lymph node metastasis (LNM), tumor infiltration/non-encapsulation and poor prognosis. The exact mechanism by which CK19 expression results in poor prognosis remains unclear. Through the use of an Affymetrix U133A oligonucleotide microarray [20 patients with hepatitis B virus (HBV)-HCC], it was demonstrated that cadherin 17 (CDH17) significantly correlated with CK19 expression (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.